Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Conditions:   Parathyroid Carcinoma;   Primary Hyperparathyroidism
Intervention:   Drug: KHK7580
Sponsor:   Kyowa Hakko Kirin Co., Ltd
Recruiting - verified September 2017

http://ift.tt/2vRcP4F